Secarna Pharmaceuticals Announces Publication of New Preclinical Data Showing Durable Antitumor Activity of LNAplus(TM)-Based ASOs that Both Stimulate the Innate Immune System and Suppress PD-L1 Expression
KRQE,
Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC) Secarna's LNAplus™-bas…